Gadolinium – a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?

Cowper SE, Su L, Robin H, Bhawan J, LeBoit PE. Nephrogenic fibrosing dermopathy. Am J Dermatopathol2001; 23: 383–393

Swartz RD, Crofford LJ, Phan SH, Ike RW, Su LD. Nephrogenic fibrosing dermopathy: a novel cutaneous fibrosing disorder in patients with renal failure. Am J Med2003; 114: 563–572

Cowper SE. Nephrogenic fibrosing dermopathy: the first six Years. Curr Opin Rheumatol2003; 15: 785–790

Leboit PE. What nephrogenic fibrosing dermopathy might be. Arch Dermatol2003; 139: 928–930

Ting WW, Stone MS, Madison KC, Kurtz K. Nephrogenic fibrosing dermopathy with systemic involvement. Arch Dermatol2003; 139: 903–906

Daram SR, Cortese CM, Bastani B. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: report of a new case with literature review. Am J Kidney Dis2005; 46: 754–759

McNeill AM, Barr RJ. Scleromyxedema-like fibromucinosis in a patient undergoing hemodialysis. Int J Dermatol2002; 41: 364–367

Joffe P, Thomsen HS, Meusel M. Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol1998; 5: 491–502

Mann JS. Stability of gadolinium complexes in vitro and in vivo. J Comput Assist Tomogr1993; 17: S19–S23

Vorobiov M, Basok A, Tovbin D, Shnaider A, Katchko L, Rogachev B. Iron-mobilizing properties of the gadolinium – DTPA complex: clinical and experimental observations. Nephrol Dial Transplant2003; 18: 884–887

Jimenez SA, Artlett CM, Sandorfi N et al. Nephrogenic fibrosing dermopathy: study of inflammatory cells and transforming growth factor beta1 expression in affected skin. Arthritis Rheum2004; 50: 2660–2666

Cowper SE, Bucala R. Nephrogenic fibrosing dermopathy: suspect identified, Motive Unclear. [Letter]. Am J Dermatopathol2003; 25: 358

Quan TE, Cowper S, Wu SP, Bockenstedt LK, Bucala R. Circulating fibrocytes: collagen – secreting cells of the peripheral blood. Int J Biochem Cell Biol2004; 36: 598–606

Mackay-Wiggan JM, Cohen DJ, Hardy MA, Knobler EH, Grossman ME. Nephrogenic fibrosing dermopathy (scleromyxedema-like illness of renal disease). Am Acad Dermatol2003; 48: 55–60

Fazeli A, Lio PA, Liu V. Nephrogenic fibrosing dermopathy: are ACE inhibitors the missing link? [Letter]. Arch Dermatol2004; 140: 1401

Cowper SE. Nephrogenic systemic fibrosis: the nosological and conceptual evolution of nephrogenic fibrosing dermopathy. Am J Kidney Dis2005; 46: 763–765

Baron PW, Cantos K, Hillebrand DJ et al. Nephrogenic fibrosing dermopathy after liver transplantation successfully treated with plasmapheresis. Am J Dermatopathol2003; 25: 204–209

Gilliet M, Cozzio A, Burg G, Nestle FO. Successful treatment of three cases of nephrogenic fibrosing dermopathy with extracorporal photopheresis. Br J Dermatol2005; 152: 531–536

Moschella SL, Kay J, Mackool BT, Liu V. Case 35–2004. A 68-year-old man with end stage renal disease and thickening of the skin. N Engl J Med2004; 351: 2219–2227

Vicktor C., Schultz-Ehrenburg U. Papulosis maligna atrophicans (Köhlmeier – Degos) Hautarzt2001; 52; 734–737

Littler CM, Tschen EH. Pentoxifylline for necrobiosis lipoidica diabeticorum. J Am Acad Dermatol1987; 17: 314–316